Boaz Hirshberg, MD

Articles by Boaz Hirshberg, MD

Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease

ByDavid M. Kern, MS,Stephanie DeVore, MSPH,Jennifer Kim, PharmD,Ozgur Tunceli, PhD,Bingcao Wu, MS,Boaz Hirshberg, MD

March 18th 2015

Targeting glucose control and managing cardiovascular (CV) risk factors may prevent future CV events, and have positive downstream impact by reducing costs to healthcare stakeholders.

Latest Updated Articles

Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease
Published: March 18th 2015 | Updated:

Boaz Hirshberg, MD

Articles by Boaz Hirshberg, MD

Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease

Latest Updated Articles

Trending on AJMC

Real-World Data Support Dual Benefit of Biologic Therapy for Hidradenitis Suppurativa

AI-Driven Research Toolkit Links Aging Biology and Fibrotic Disease

Lubiprostone May Offer Renoprotection in CKD

Tarlatamab, PD-L1 Inhibitor Combo Shows Promise in 1L Maintenance for ES-SCLC

There Is Urgent Need to Integrate Respiratory and Palliative Care: Natasha Smallwood, BMedSci, MBBS, MSc